biodiversidad (@_biodiversa) header
biodiversidad (@_biodiversa) profile picture

#wetware: conservación, tecnología, economía de genes. reservas estratégicas de ADN. mercados de información. economía post-genómica, post-petrolera

California, Ecuador
Joined May 2012
Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)
AI training = fair use openai.com/new-york-times/ DOJ sides with OpenAI in New York Times copyright suit nytimes.com/2026/09/02/techn… data retention is your treasure teapawt.net/_biodiversa/status/207… whose data? teapawt.net/_biodiversa/status/206… digital sequence information #DSI
9
an entirely new way to make medicine teapawt.net/_biodiversa/status/211… as soon as digital sequence information was posted teapawt.net/_biodiversa/status/162… digital sequence information #DSI
💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster. We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America. I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.
6
biodiversidad retweeted
Monsanto Canada Inc. v. Schmeiser decisions.scc-csc.ca/scc-csc… the new oil teapawt.net/_biodiversa/status/160… patents, risk teapawt.net/_biodiversa/status/160… digital sequence information #DSI
what is the legal definition of "genetic resource" and "digital sequence information"? what does "as applicable" mean? who defines fairness and equitability? patents, risk? teapawt.net/_biodiversa/status/160… @OscarALizarazo @KlausRiede @synbiomaria @aysirakaya @Basecamp_Res thanks!
1
3
1
2
286
wonder plants teapawt.net/_biodiversa/status/150… an entirely new way to make medicine teapawt.net/_biodiversa/status/162… patents teapawt.net/_biodiversa/status/161… royalties teapawt.net/_biodiversa/status/160… digital sequence information #DSI
That’s huge - welcome to the Bioeconomy
16
biodiversidad retweeted
Aichi Target 5: habitat loss, not achieved teapawt.net/_biodiversa/status/139… royalties as low as 0.01%, gene patents teapawt.net/_biodiversa/status/150… bioeconomy, US$0.5-1.4 trillion teapawt.net/LBNLBioSci/status/1359… industria del ADN teapawt.net/_biodiversa/status/149… #DSI #Nagoya
A new #BioScience Viewpoint offers community-generated recommendations for enabling effective access and benefit sharing of digital sequence information.#aibs #journal academic.oup.com/bioscience/…
biology, defense teapawt.net/_biodiversa/status/162… digital sequence information #DSI
How does machine intelligence change how we should think about biodefense? Looking forward to speaking tomorrow on this at the @OpenAI forum, and especially feeling grateful to be in conversation with the other panelists!
23
biodiversidad retweeted
Yes
Biotech still runs on who owns the patent and who approves the drug. That was my takeaway from @alexkesin's session at DataDrivenPharma West last week. Alex wrote one of the most widely shared analyses of China's biotech rise this year, and it has become a reference point in the policy debate. He also co-hosts @approvedfm with [@MatthewPech], a podcast on how drugs get discovered, developed and sold. He walked a room of operators through where the value sits now. Four quick hits: - 1:3. Doing the work in China costs a half to a third of the US price. - Rent, don't sell. Beijing's new export controls block the sale of biotech platforms. Licensing, partnerships and contract research stay open. - 3x. China tripled its university patent conversion rate in two years, to 10.1%. - 8% to 32%. China's share of the global early-stage pipeline, from 2015 to 2024. The first hit explains the last five years. China got cheap and fast, and the West bought what it built. Most of those deals were fast-follows on targets Western labs discovered. The West owned the original IP and rented China's speed. The other three point to the next five. The export controls dropped the same morning as the session. Read them next to the new five-year plan, which makes biotech and biomanufacturing a national priority through 2030. The strategy looks clear to me. Generate IP faster than the US, keep ownership at home, and let the world license it. Pipeline share has quadrupled. Patents are moving out of universities and into companies. Nine out of ten still sit unused, so there's plenty of room to grow. Patents are still the currency. Regulators still set the exchange rate. The FDA turned away a Chinese PD-1 copycat because its trial ran only on Chinese patients. To get paid in the US, you still need FDA approval and a partner who can launch here. What changes is who holds the paper. When the West generated the IP, licensing meant Western companies owned the value and paid for speed. As more IP is generated and kept in China, the same deal structure sends more value the other way. The West ends up renting the molecule instead of owning it. This is a gold rush for intellectual property. The question is who can generate novel IP in a specific area, and do it first. Therapeutics is the beachhead. The US market pays enough for new drugs that the long road through the FDA still earns a return. In this gold rush, anyone can be a miner. The fastest ones will have the best maps. And maps only come from data. #ddpwest26
3
10
1,060
Costa Rica, 2024 certification: benefit sharing commitments, prior informed consent, mutually agreed terms medium.com/@basecamp-researc… 2026 antibiotic, vaccine design; #Claude: >30 countries, >10 billion new DNA sequences prnewswire.com/news-releases… Digital Sequence Information #DSI
2. Data retention is your treasure. Transferring data hands over access to your pre-existing winning plays, yields means of production for new ones biology 1 teapawt.net/_biodiversa/status/206… 2 teapawt.net/_biodiversa/status/207… patents teapawt.net/_biodiversa/status/150… digital sequence information #DSI
29
Amazon’s new AI Bio Discovery tool can provide ‘every researcher’ with ‘lab-in-the-loop drug discovery’ – 40+ AI biology models can filter 300,000 novel antibody candidates down to the top results for testing in just weeks | @techradar techradar.com/pro/amazons-ne…
2
2
682
biodiversidad retweeted
14 (a) Should economic rent be charged for access to genetic resources? What should be the basis for the valuation of such rent? cbd.int/decision/cop?id=1165… Ozempic, ~US$14 billion qz.com/ozempic-weight-loss-d… digital sequence information #DSI
Replying to @_biodiversa
Enclosure A (a) Pharmaceuticals; (d) Biotechnology; (f) Information, scientific, technical services related to #DSI on genetic resources including AI (?) cbd.int/doc/c/8125/22ca/baa2… IP, risk teapawt.net/_biodiversa/status/180…
1
1
28
biodiversidad retweeted
The synthetic biology revolution is upon us, and its TRILLIONs of dollars of value to be created. SynBioBeta has their conference again in Oakland May 23-25 I urge you to go or to follow what is happening. forbes.com/sites/johncumbers…
44
120
32
558
126,350
2. Data retention is your treasure. Transferring data hands over access to your pre-existing winning plays, yields means of production for new ones biology 1 teapawt.net/_biodiversa/status/206… 2 teapawt.net/_biodiversa/status/207… patents teapawt.net/_biodiversa/status/150… digital sequence information #DSI
Our thoughts on the importance of AI sovereignty. 1. Your AI sovereignty dictates your institution’s future. Sovereignty is the precondition for choice. Relinquishing sovereignty transfers the future choices of your institution to others, who are likely to exploit it for their gain and your loss. 2. Data retention is your treasure. Transfer it at your own peril. Your ability to win is dictated by your ability to recognize and use your unique edges, and you keep winning by compounding the underlying data to generate new insights. Transferring that data hands over access to your pre-existing winning plays and yields the means of production for new ones. 3. Tokenmaxxing hijacks your value orientation and decreases your institutional fortitude and intelligence. The pursuit of high token usage incentivizes disposable scripts over robust software — with the addictive feeling of false progress. There is a reason why those selling tokens refuse to charge based on value. 4. Controlling your weights is controlling your fate. Weights are the distilled form of hard-won, accumulated institutional knowledge. If you let others control your weights, you are allowing them to migrate the alpha of your business to theirs. 5. There is no contradiction between sovereignty and alpha. The architecture that maximally preserves sovereignty is one that enables institutions to own their tribal knowledge, and to compound it as alpha. 6. Politicizing the technical issues involving sovereignty is what your adversary wants. Techno-politicization is the wellspring of false sovereignty. Techno-politicization drives decisions that seem to reduce dependency, but ultimately limit agency — especially on the battlefield in the West. 7. Real expertise is existential. Allowing politics or favoritism to determine your technical decisions rewards whoever is best at politics, not whoever is right. Listen to those closest to the problems, not those speaking most compellingly about them. 8. Learn from institutions that are winning or that have consistently delivered. Institutions facing existential threats do not have the luxury of making technical decisions based on political preferences. 9. Only listen to institutions, countries, and people who have a proven record of being right. A track record of correctness is the best and only signal for future correctness. Judging something as right or wrong based on who you like is exceedingly misguided.
1
41
biodiversidad retweeted
predict lab-of-origin of engineered DNA nature.com/articles/s41467-0… country of origin? countries exercise sovereign rights over genetic resources teapawt.net/_biodiversa/status/128… those prized genes can be assembled in a laboratory to churn out anything teapawt.net/_biodiversa/status/125… #DSI #Nagoya
drivendata.org/competitions/… Your goal is to create an algorithm that identifies the most likely lab-of-origin for genetically engineered DNA.
2
3
biodiversidad retweeted
genome privacy teapawt.net/_biodiversa/status/165… digital sequence information #DSI
#BioNFTs 🧬 (thread 🧵): 1/ #BioNFTs are a new way for patients to own and control their biosample-derived data, such as #DNA, in a centralized or decentralized storage protocol.
2
3
133